[Targeted anticancer drugs and their development].
Kervinen
Jukka
J
3-Dimensional Pharmaceuticals, Johnson & Johnson Pharmaceutical Research Division, Exton, Pennsylvania 19341, USA. jkervine@prdus.jnj.com
Gahmberg
Carl G
CG
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D049109:Cell Proliferation / Q000187:drug effects; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate